• Je něco špatně v tomto záznamu ?

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer

M. Svaton, M. Bratova, L. Koubkova, O. Fischer, B. Melichar, M. Hrnciarik, D. Dolezal, O. Bilek, J. Krejci, M. Drosslerova, Z. Dlouha, J. Blazek, P. Majkova, L. Brozova, M. Stastny

. 2022 ; 42 (4) : 1987-1995. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018902

AIM: This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. PATIENTS AND METHODS: The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). RESULTS: We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. CONCLUSION: From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexed-based one.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018902
003      
CZ-PrNML
005      
20220804135155.0
007      
ta
008      
220720s2022 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.15677 $2 doi
035    __
$a (PubMed)35347019
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Svaton, Martin $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic; svatonm@fnplzen.cz
245    10
$a Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer / $c M. Svaton, M. Bratova, L. Koubkova, O. Fischer, B. Melichar, M. Hrnciarik, D. Dolezal, O. Bilek, J. Krejci, M. Drosslerova, Z. Dlouha, J. Blazek, P. Majkova, L. Brozova, M. Stastny
520    9_
$a AIM: This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. PATIENTS AND METHODS: The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). RESULTS: We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. CONCLUSION: From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexed-based one.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    12
$a nemalobuněčný karcinom plic $x patologie $7 D002289
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x patologie $7 D008175
650    _2
$a nivolumab $x terapeutické užití $7 D000077594
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bratova, Monika $u Department of Respiratory Diseases, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Koubkova, Leona $u Department of Pneumology, 2 Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Fischer, Ondrej $u Department of Respiratory Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Hrnciarik, Michal $u Department of Pneumology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Dolezal, Daniel $u Department of Pneumology, Masaryk Hospital, Usti nad Labem, Czech Republic
700    1_
$a Bilek, Ondrej $u Department of Oncology, Masaryk Institute of Oncology, Brno, Czech Republic
700    1_
$a Krejci, Jana $u Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic
700    1_
$a Drosslerova, Marie $u Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic
700    1_
$a Dlouha, Zdenka $u Department of Oncology, General University Hospital, 1 Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Blazek, Jiri $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Majkova, Petra $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Brozova, Lucie $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Stastny, Marek $u BMS Czech Republic, Prague, Czech Republic
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 42, č. 4 (2022), s. 1987-1995
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35347019 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135149 $b ABA008
999    __
$a ok $b bmc $g 1822477 $s 1170145
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 42 $c 4 $d 1987-1995 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

    Možnosti archivace